



- (51) **International Patent Classification:**
C07D 487/04 (2006.01) **A61P 29/00** (2006.01)
A61K 31/4162 (2006.01)
- (21) **International Application Number:**
PCT/US2013/055275
- (22) **International Filing Date:**
16 August 2013 (16.08.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/683,780 16 August 2012 (16.08.2012) US
- (71) **Applicant:** JANSSEN PHARMACEUTICA NV
[BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).
- (72) **Inventor; and**
- (71) **Applicant :** WINTERS, Michael, P. [US/US]; 17
Hunters Hill Drive, Morgantown, PA 19543 (US).
- (72) **Inventor:** SUI, Zhihua; 36 Birchview Drive, Piscataway,
NJ 08854 (US).
- (74) **Agents:** JOHNSON, Philip, S. et al.; JOHNSON &
JOHNSON, One Johnson & Johnson Plaza, New Brun-
swick, NJ 08933 (US).
- (81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

- (84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

Published:

— *with international search report (Art. 21(3))*

- (54) **Title:** PYRROLOPYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS



(I)

- (57) **Abstract:** Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: Formula. (I) wherein R¹, R², R³, Q, and G are defined herein.